There were significant decreases in p‐AKT/AKT, p‐mTOR/mTOR, and PD‐L1 in DTLL‐treated tumor samples with the same inhibitory trends in the ratios of p‐EGFR/EGFR and p‐HER2/HER2. The gene discussed is EGFR; the disease is neoplasm.